Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens

Leukemia

Volumn 25, Issue 7, 2011, Pages 1197-1200

  Kraljacic, B C ^a   Arguello, M ^a   Amri, A ^a   Cormack, G ^a   Borden, K ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTARABINE; IDARUBICIN; INITIATION FACTOR 4E; METHYLCELLULOSE; RIBAVIRIN; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TISSUE SECTION;

EID: 79960245689     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.57     Document Type: Article

References (12)

1. Martin MG, Abboud CN. Induction therapy for elderly patients with acute myeloid leukemia. Blood Rev 2008; 22: 311-320.
2. Borden KL, Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma 2010; 51: 1805-1815.
3. Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ et al. Aberrant eukaryotic translation initiation factor 4Edependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 2003; 23: 8992-9002. (Pubitemid 37499790)
4. Culjkovic B, Topisirovic I, Borden KL. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 2007; 6: 65-69. (Pubitemid 46173883)
5. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 2001; 20: 4547-4559. (Pubitemid 32772048)
6. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 2004; 101: 18105-18110. (Pubitemid 40054081)
7. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009; 114: 257-260.
8. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184-198. (Pubitemid 351480557)
9. Abdel-Wahab O, Levine RL. Recent advances in the treatment of acute myeloid leukemia. F1000 Med Rep 2010; 2: 55.
10. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 2004; 64: 8639-8642. (Pubitemid 39552077)
11. Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P et al. Tumorspecific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 2009; 113: 443-456.
12. Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM et al. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol 2010. E-pub ahead of print 22 July 2010.